These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 20156115)

  • 1. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.
    Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Hamilton-Dutoit S; Garne JP; Ewertz M; Sørensen HT; Pedersen L
    Acta Oncol; 2010 Apr; 49(3):305-12. PubMed ID: 20156115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.
    Lash TL; Pedersen L; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Hamilton-Dutoit S; Garne JP; Ewertz M; Sørensen HT
    Br J Cancer; 2008 Aug; 99(4):616-21. PubMed ID: 18665165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.
    Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Garne JP; Sørensen HT; Hellberg Y; Christensen M; Pedersen L; Hamilton-Dutoit S
    J Natl Cancer Inst; 2011 Mar; 103(6):489-500. PubMed ID: 21325141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.
    Kelly CM; Juurlink DN; Gomes T; Duong-Hua M; Pritchard KI; Austin PC; Paszat LF
    BMJ; 2010 Feb; 340():c693. PubMed ID: 20142325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?
    Pritchard KI
    Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S18. PubMed ID: 21172080
    [No Abstract]   [Full Text] [Related]  

  • 6. Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality.
    Cronin-Fenton D; Lash TL; Sørensen HT
    Future Oncol; 2010 Jun; 6(6):877-80. PubMed ID: 20528223
    [No Abstract]   [Full Text] [Related]  

  • 7. Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors.
    Haque R; Shi J; Schottinger JE; Ahmed SA; Cheetham TC; Chung J; Avila C; Kleinman K; Habel LA; Fletcher SW; Kwan ML
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26631176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study.
    Valachis A; Garmo H; Weinman J; Fredriksson I; Ahlgren J; Sund M; Holmberg L
    Breast Cancer Res Treat; 2016 Sep; 159(2):293-303. PubMed ID: 27492739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
    Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
    J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications.
    Ahern TP; Pedersen L; Cronin-Fenton DP; Sørensen HT; Lash TL
    Cancer Epidemiol Biomarkers Prev; 2009 Sep; 18(9):2562-4. PubMed ID: 19690182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
    Rae JM; Drury S; Hayes DF; Stearns V; Thibert JN; Haynes BP; Salter J; Sestak I; Cuzick J; Dowsett M;
    J Natl Cancer Inst; 2012 Mar; 104(6):452-60. PubMed ID: 22395643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
    Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
    J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
    Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
    J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer.
    Lash TL; Gurwitz JH; Silliman RA
    J Am Geriatr Soc; 2005 Nov; 53(11):1889-96. PubMed ID: 16274369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study.
    Donneyong MM; Bykov K; Bosco-Levy P; Dong YH; Levin R; Gagne JJ
    BMJ; 2016 Sep; 354():i5014. PubMed ID: 27694571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Punglia RS; Burstein HJ; Winer EP; Weeks JC
    J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence.
    Azoulay L; Dell'Aniello S; Huiart L; du Fort GG; Suissa S
    Breast Cancer Res Treat; 2011 Apr; 126(3):695-703. PubMed ID: 20848186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study.
    Busby J; Mills K; Zhang SD; Liberante FG; Cardwell CR
    Breast Cancer Res; 2018 Jan; 20(1):4. PubMed ID: 29351761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen and CYP 2D6 inhibitors: caution.
    Prescrire Int; 2011; 20(118):182-4. PubMed ID: 21751753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.